drugset / Trial / NCT02405676

Summary

The purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with the historical study CCCG-NHL-2010.

Timeline

Start
2015-01-01
Primary completion
2023-12-31
Completion
2029-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 200 mg/m2
Subject Cyclophosphamide Other / unclassified 300 mg/m2
Subject Cytarabine Small molecule 1 g
Subject Cytarabine Small molecule 2 g
Subject Etoposide Small molecule 60 mg/m2
Subject Etoposide Small molecule 100 mg/m2
Subject Methotrexate Small molecule 0.5 g
Subject Methotrexate Small molecule 5 g
Subject Prednisone Other / unclassified 45 mg/m2
Subject Prednisone Other / unclassified 60 mg/m2
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Vindelsine Unknown 3 mg/m2
Background Doxorubincin Unknown 20 mg/m2
Background Ifosfamide Small molecule 1.2 g/kg
Background Vincristine Small molecule 1.5 mg/m2